Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015

Description: Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015

Summary

This, ‘Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015’, provides an overview of the Prader-Willi Syndrome (PWS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Prader-Willi Syndrome (PWS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Prader-Willi Syndrome (PWS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Prader-Willi Syndrome (PWS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Prader-Willi Syndrome (PWS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
- List of Tables
- List of Figures
- Introduction
- REPORT COVERAGE
- Prader-Willi Syndrome (PWS) Overview
- Therapeutics Development
- Pipeline Products for Prader-Willi Syndrome (PWS) – Overview
- Pipeline Products for Prader-Willi Syndrome (PWS) – Comparative Analysis
- Prader-Willi Syndrome (PWS) – Therapeutics under Development by Companies
- Prader-Willi Syndrome (PWS) – Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Prader-Willi Syndrome (PWS) – Products under Development by Companies
- Prader-Willi Syndrome (PWS) – Companies Involved in Therapeutics Development
  - Chong Kun Dang Pharmaceutical Corp.
  - Essentials, Inc.
  - Ferring International Center S.A.
  - LG Life Sciences, Ltd.
  - P2D Bioscience
  - Pfizer Inc.
  - Rhythm Pharmaceuticals
  - Prader-Willi Syndrome (PWS) – Therapeutics Assessment
    - Assessment by Monotherapy Products
    - Assessment by Target
    - Assessment by Mechanism of Action
    - Assessment by Route of Administration
    - Assessment by Molecule Type
- Drug Profiles
  - beloranib - Drug Profile
    - Product Description
    - Mechanism of Action
    - R&D Progress
  - betahistine hydrochloride - Drug Profile
    - Product Description
    - Mechanism of Action
    - R&D Progress
  - diazoxide choline CR - Drug Profile
    - Product Description
    - Mechanism of Action
    - R&D Progress
  - FE-992097 - Drug Profile
    - Product Description
    - Mechanism of Action
    - R&D Progress
  - NOX-B11 - Drug Profile
    - Product Description
    - Mechanism of Action
    - R&D Progress
  - setmelanotide - Drug Profile
    - Product Description
    - Mechanism of Action
    - R&D Progress
  - somatropin SR - Drug Profile
    - Product Description
Mechanism of Action
R&D Progress
Prader-Willi Syndrome (PWS) – Recent Pipeline Updates
Prader-Willi Syndrome (PWS) – Product Development Milestones
Featured News & Press Releases
Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research
Oct 01, 2014: Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome
Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome
Jun 27, 2014: Essentialis Announces the Dosing of the First Patient in a Clinical Study of DCCR in Prader-Willi Syndrome
May 28, 2014: Essentialis Obtains Orphan Drug Designation from FDA for DCCR in the Treatment of Prader-Willi Syndrome
Jan 15, 2014: Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2015
Number of Products under Development for Prader-Willi Syndrome (PWS) – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Prader-Willi Syndrome (PWS) – Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015
Prader-Willi Syndrome (PWS) – Pipeline by Essentialis, Inc., H1 2015
Prader-Willi Syndrome (PWS) – Pipeline by Ferring International Center S.A., H1 2015
Prader-Willi Syndrome (PWS) – Pipeline by LG Life Sciences, Ltd., H1 2015
Prader-Willi Syndrome (PWS) – Pipeline by P2D Bioscience, H1 2015
Prader-Willi Syndrome (PWS) – Pipeline by Pfizer Inc., H1 2015
Prader-Willi Syndrome (PWS) – Pipeline by Rhythm Pharmaceuticals, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Prader-Willi Syndrome (PWS) Therapeutics – Recent Pipeline Updates, H1 2015

List of Figures
Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2015
Number of Products under Development for Prader-Willi Syndrome (PWS) – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Ordering:

Order Online - http://www.researchandmarkets.com/reports/3099705/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3099705/">http://www.researchandmarkets.com/reports/3099705/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2AZWO</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof] [ ]

First Name: ___________________________________________          Last Name: ___________________________________________

Email Address: * _____________________________________________

Job Title: ___________________________________________________

Organisation: _______________________________________________

Address: ___________________________________________________

City: _______________________________________________________

Postal / Zip Code: ___________________________________________

Country: ___________________________________________________

Phone Number: ______________________________________________

Fax Number: __________________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- [ ] Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

- [ ] Pay by check: Please post the check, accompanied by this form, to:

  Research and Markets,
  Guinness Center,
  Taylors Lane,
  Dublin 8,
  Ireland.

- [ ] Pay by wire transfer: Please transfer funds to:

  - Account number: 833 130 83
  - Sort code: 98-53-30
  - Swift code: ULSBIE2D
  - IBAN number: IE78ULSB98533083313083
  - Bank Address: Ulster Bank,
    27-35 Main Street,
    Blackrock,
    Co. Dublin,
    Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp